Search Results - "Phan, See"

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial by Nishio, Makoto, Barlesi, Fabrice, West, Howard, Ball, Simon, Bordoni, Rodolfo, Cobo, Manuel, Longeras, Pascale Dubray, Goldschmidt, Jr, Jerome, Novello, Silvia, Orlandi, Francisco, Sanborn, Rachel E, Szalai, Zsuzsanna, Ursol, Grigoriy, Mendus, Diana, Wang, Lijia, Wen, Xiaohui, McCleland, Mark, Hoang, Tien, Phan, See, Socinski, Mark A

“…We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with…”
Get more information

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer by ROBERT, Nicholas J, DIERAS, Véronique, PHAN, See-Chun, O'SHAUGHNESSY, Joyce, GLASPY, John, BRUFSKY, Adam M, BONDARENKO, Igor, LIPATOV, Oleg N, PEREZ, Edith A, YARDLEY, Denise A, CHAN, Stephen Y. T, XIAN ZHOU

“…This phase III study compared the efficacy and safety of bevacizumab (BV) when combined with several standard chemotherapy regimens versus those regimens alone…”
Get full text

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer by SPIGEL, David R, ERVIN, Thomas J, GOVINDAN, Ramaswamy, PATEL, Taral, ORLOV, Sergey V, WERTHEIM, Michael S, WEI YU, JIPING ZHA, YAUCH, Robert L, PATEL, Premal H, PHAN, See-Chun, PETERSON, Amy C, RAMLAU, Rodryg A, DANIEL, Davey B, GOLDSCHMIDT, Jerome H, BLUMENSCHEIN, George R, KRZAKOWSKI, Maciej J, ROBINET, Gilles, GODBERT, Benoit, BARLESI, Fabrice

“…Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal growth factor receptor (EGFR) -targeted…”
Get full text

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung by Spigel, David R, Edelman, Martin J, O'Byrne, Kenneth, Paz-Ares, Luis, Mocci, Simonetta, Phan, See, Shames, David S, Smith, Dustin, Yu, Wei, Paton, Virginia E, Mok, Tony

“…Purpose The phase III OAM4971g study (METLung) examined the efficacy and safety of onartuzumab plus erlotinib in patients with locally advanced or metastatic…”
Get full text

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial by Kim, Edward S., Velcheti, Vamsidhar, Mekhail, Tarek, Yun, Cindy, Shagan, Sarah M., Hu, Sylvia, Chae, Young Kwang, Leal, Ticiana A., Dowell, Jonathan E., Tsai, Michaela L., Dakhil, Christopher S. R., Stella, Philip, Jin, Yanling, Shames, David S., Schleifman, Erica, Fabrizio, David A., Phan, See, Socinski, Mark A.

“…Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies…”
Get full text

Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer by Sathe, Abhishek G., Diderichsen, Paul M., Fauchet, Floris, Phan, See‐Chun, Girish, Sandhya, Othman, Ahmed A.

“…Sacituzumab govitecan (SG), a Trop‐2‐directed antibody‐drug conjugate, is approved for patients with metastatic triple‐negative breast cancer (mTNBC) who…”
Get full text

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC by Jassem, Jacek, de Marinis, Filippo, Giaccone, Giuseppe, Vergnenegre, Alain, Barrios, Carlos H, Morise, Masahiro, Felip, Enriqueta, Oprean, Cristina, Kim, Young-Chul, Andric, Zoran, Mocci, Simonetta, Enquist, Ida, Komatsubara, Kimberly, McCleland, Mark, Kuriki, Hiroshi, Villalobos, Monette, Phan, See, Spigel, David R, Herbst, Roy S

“…IMpower110 previously revealed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR- and…”
Get more information

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression by Bardia, Aditya, Rugo, Hope S, Tolaney, Sara M, Loirat, Delphine, Punie, Kevin, Oliveira, Mafalda, Brufsky, Adam, Kalinsky, Kevin, Cortés, Javier, Shaughnessy, Joyce O', Diéras, Véronique, Carey, Lisa A, Gianni, Luca, Piccart-Gebhart, Martine, Loibl, Sibylle, Yoon, Oh Kyu, Pan, Yang, Hofsess, Scott, Phan, See-Chun, Hurvitz, Sara A

“…JCO Sacituzumab govitecan (SG), a first-in-class anti-trophoblast cell surface antigen 2 (Trop-2) antibody-drug conjugate, demonstrated superior efficacy over…”
Get full text

A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer by Bendell, Johanna C., Hochster, Howard, Hart, Lowell L., Firdaus, Irfan, Mace, Joseph R., McFarlane, Joshua J., Kozloff, Mark, Catenacci, Daniel, Hsu, Jessie J., Hack, Stephen P., Shames, David S., Phan, See‐Chun, Koeppen, Hartmut, Cohn, Allen L.

“…Background Dysregulated hepatocyte growth factor/mesenchymal‐epithelial transition (MET) signaling is associated with poor prognosis and resistance to vascular…”
Get full text

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit by KOEPPEN, Hartmut, WEI YU, LING FU, AN DO, PARAB, Vaishali, XIAOLING XIA, JANUARIO, Tom, LOUIE, Sharianne G, FILVAROFF, Ellen, SHAMES, David S, WISTUBA, Ignacio, LIPKIND, Marina, JIPING ZHA, HUANG, Jenny, LAZAROV, Mirella, RAMAKRISHNAN, Vanitha, AMLER, Lukas, PHAN, See-Chun, PATEL, Premal, PETERSON, Amy, YAUCH, Robert L, PANDITA, Ajay, PENUEL, Elicia, RANGELL, Linda, RAJA, Rajiv, MOHAN, Sankar, PATEL, Rajesh, DESAI, Rupal

“…In a recent phase II study of onartuzumab (MetMAb), patients whose non-small cell lung cancer (NSCLC) tissue scored as positive for MET protein by…”
Get full text

Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma by Cruickshanks, Nichola, Zhang, Ying, Hine, Sarah, Gibert, Myron, Yuan, Fang, Oxford, Madison, Grello, Cassandra, Pahuski, Mary, Dube, Collin, Guessous, Fadila, Wang, Baomin, Deveau, Ciana, Saoud, Karim, Gallagher, Isela, Wulfkuhle, Julia, Schiff, David, Phan, See, Petricoin, Emanuel, Abounader, Roger

“…Glioblastoma (GBM) is the most common and most lethal primary malignant brain tumor. The receptor tyrosine kinase MET is frequently upregulated or…”
Get full text

Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial by Mehta, Minesh P., M.D, Shapiro, William R., M.D, Phan, See C., M.D, Gervais, Radj, M.D, Carrie, Christian, M.D, Chabot, Pierre, M.D, Patchell, Roy A., M.D, Glantz, Michael J., M.D, Recht, Lawrence, M.D, Langer, Corey, M.D, Sur, Ranjan K., M.D., Ph.D, Roa, Wilson H., M.D, Mahe, Marc A., M.D, Fortin, Andre, M.D, Nieder, Carsten, M.D, Meyers, Christina A., Ph.D, Smith, Jennifer A., Ph.D, Miller, Richard A., M.D, Renschler, Markus F., M.D

“…Purpose To determine the efficacy of motexafin gadolinium (MGd) in combination with whole brain radiotherapy (WBRT) for the treatment of brain metastases from…”
Get full text

Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program by Morley, Roland, Cardenas, Alison, Hawkins, Peter, Suzuki, Yasuyo, Paton, Virginia, Phan, See-Chun, Merchant, Mark, Hsu, Jessie, Yu, Wei, Xia, Qi, Koralek, Daniel, Luhn, Patricia, Aldairy, Wassim

“…Onartuzumab, a recombinant humanized monovalent monoclonal antibody directed against MET, the receptor for the hepatocyte growth factor, has been investigated…”
Get full text

Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor–Positive, Metastatic Carcinoma of the Breast in Premenopausal Women by CARLSON, Robert W, THERIAULT, Richard, VALERO, Vicente, SCHURMAN, Christine M, RIVERA, Edgardo, CHUNG, Cathie T, PHAN, See-Chun, ARUN, Banu, DICE, Kristine, CHIV, Vivian Y, GREEN, Marjorie

“…To explore the antitumor activity of the aromatase inhibitor, anastrozole, in the treatment of premenopausal women with hormone receptor-positive, metastatic…”
Get full text

Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial by MEYERS, Christina A, SMITH, Jennifer A, SIEMERS, Ross, CARRIE, Christian, GASPAR, Laurie E, CURRAN, Walter, PHAN, See-Chun, MILLER, Richard A, RENSCHLER, Markus F, BEZJAK, Andrea, MEHTA, Minesh P, LIEBMANN, James, ILLIDGE, Tim, KUNKLER, Lan, CAUDRELIER, Jean-Michel, EISENBERG, Peter D, MEERWALDT, Jacobus

“…To report the neurocognitive findings in a phase III randomized trial evaluating survival and neurologic and neurocognitive function in patients with brain…”
Get full text

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis by Carey, Lisa A., Loirat, Delphine, Punie, Kevin, Bardia, Aditya, Diéras, Véronique, Dalenc, Florence, Diamond, Jennifer R., Fontaine, Christel, Wang, Grace, Rugo, Hope S., Hurvitz, Sara A., Kalinsky, Kevin, O’Shaughnessy, Joyce, Loibl, Sibylle, Gianni, Luca, Piccart, Martine, Zhu, Yanni, Delaney, Rosemary, Phan, See, Cortés, Javier

“…Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial,…”
Get full text

Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases by MEHTA, Minesh P, RODRIGUS, Patrick, SCHULTZ, Christopher, TIMMERMAN, Robert, CURRAN, Walter, SMITH, Jennifer, PHAN, See-Chun, MILLER, Richard A, RENSCHLER, Markus F, TERHAARD, C. H. J, RAO, Aroor, SUH, John, ROA, Wilson, SOUHAMI, Luis, BEZJAK, Andrea, LEIBENHAUT, Mark, KOMAKI, Ritsuko

“…This phase III randomized trial evaluated survival as well as neurologic and neurocognitive function in patients with brain metastases from solid tumors…”
Get full text

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer by Hurvitz, Sara A., Bardia, Aditya, Punie, Kevin, Kalinsky, Kevin, Carey, Lisa A., Rugo, Hope S., Diéras, Véronique, Phan, See, Delaney, Rosemary, Zhu, Yanni, Tolaney, Sara M.

“…In this post hoc analysis of the ASCENT study, we compared outcomes with sacituzumab govitecan (SG) vs single-agent chemotherapy in clinically important…”
Get full text

Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer by Hurvitz, Sara A., Bardia, Aditya, Punie, Kevin, Kalinsky, Kevin, Carey, Lisa A., Rugo, Hope S., Diéras, Véronique, Phan, See, Delaney, Rosemary, Zhu, Yanni, Tolaney, Sara M.

Get full text

Results of the Phase I Dose-Escalating Study of Motexafin Gadolinium With Standard Radiotherapy in Patients With Glioblastoma Multiforme by Ford, Judith M., M.D., Ph.D, Seiferheld, Wendy, M.S, Alger, Jeffrey R., Ph.D, Wu, Genevieve, Ph.D, Endicott, Thyra J., M.D, Mehta, Minesh, M.D, Curran, Walter, M.D., F.A.C.R, Phan, See-Chun, M.D

“…Purpose Motexafin gadolinium (MGd) is a putative radiation enhancer initially evaluated in patients with brain metastases. This Phase I trial studied the…”
Get full text